Potential diagnostic value of lncRNA SPRY4-IT1 in hepatocellular carcinoma

Wei, Jing; Gao, Shanshan; Zhu, Man; Luo, Ping; Xuan, Jianhua; Chai, Hongyan; Tu, Jiancheng

doi:10.3892/or.2016.4859

Cited by 55 publications

(42 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies have suggested that SPRY4-IT1 may act as molecular scaffolds for protein complexes that lack protein-protein interaction domains or can interact directly with microRNAs and prevent them from binding to mRNA, thus regulating protein synthesis [10]. In the aspect of cancer studies, SPRY4-IT1 dysregulation was found to be closely associated with tumor development and also contributed to cell proliferation, cell apoptosis and cell invasion and cell migration in different types of cancers [10, 12–14, 17]. These findings may suggest the critical function of SPRY4-IT1 in cancer progression and SPRY4-IT1 may serve as a novel biomarker for early diagnosis and prognosis in cancer patients.…”

Section: Discussionmentioning

confidence: 99%

Prognostic role of the long non-coding RNA, SPRY4 Intronic Transcript 1, in patients with cancer: a meta-analysis

et al. 2017

View full text Add to dashboard Cite

Recent studies have emphasized the important role of long non-coding RNAs (lncRNAs) in cancer development. The present study performed a meta-analysis to investigate whether lncRNA, SPRY4 Intronic Transcript 1(SPRY4-IT1) can be served as a potential biomarker for prognosis in human cancers. The eligible studies were collected by searching multiple online databases (Pubmed, EMBASE, CNKI, Web of Science and Google Scholar) and meta-analysis was performed to explore the association between the expression levels of SPRY4-IT1 and overall survival (OS), disease-free survival (DFS) and clinicopathological parameters. A total of 1329 patients from 13 studies were included for meta-analysis. The meta-analysis results showed that high expression level of SPRY4-IT1 was significantly associated with shorter OS in cancer patients (HR = 3.20, 95% CI: 2.59-3.90, P<0.001) except in the patients with non-small cell lung cancer (NSCLC). Increased SPRY4-IT1 expression level was correlated with shorter DFS in patients with gastric cancer and ovarian cancer. SPRY4-IT1 expression level was not correlated with the clinicopathological parameters including age (P = 0.37), gender (P = 0.87), tumor size (P = 0.47) and invasion depth (P = 0.52), and increased SPRY4-IT1 expression level was significantly associated with distant metastasis (odds ratio (OR) = 1.96, 95% CI: 1.24-3.08, P = 0.004), lymph node metastasis (OR = 3.96, 95% CI: 1.48-5.54, P<0.001), advanced tumor/node/metastasis stage (OR = 3.72, 95% CI = 2.91-4.76, P<0.001) and poor tumor differentiation (OR = 1.86, 95% CI = 1.35-2.58, P<0.001) in cancer patients except in patients with NSCLC. In summary, the meta-analysis results suggested that increased expression level of SPRY4-IT1 was positively associated with unfavorable prognosis and advanced features of cancers in cancer patients but not in patients with NSCLC.

show abstract

Section: Discussionmentioning

confidence: 99%

Prognostic role of the long non-coding RNA, SPRY4 Intronic Transcript 1, in patients with cancer: a meta-analysis

et al. 2017

View full text Add to dashboard Cite

show abstract

“…In addition, SPRY4-IT1 expression was upregulated in the plasma from HCC patients suggesting this one to be a good diagnostic biomarker. Combination of SPRY4-IT1 and AFP (the cut-off value of AFP was at 200 ng/mL) possessed a moderate ability for discrimination between HCC patients and controls; the area was equal to 0.80 [108] . Highly upregulated in liver cancer (HULC) lncRNA has been implicated in the regulation of hepatoma cell proliferation, since it induces HCC cells to activate EMT and then promotes tumor progression and metastasis through the miR-200a/ZEB1 signalling pathway [109] .…”

Section: Circulating Non-coding Rnamentioning

confidence: 99%

Performance of different biomarkers for the management of hepatocellular carcinoma

Rojas¹,

Sánchez‐Torrijos²,

Gil‐Gómez³

et al. 2018

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and the second cause of cancer related death due to latent liver disease, late diagnosis and non-available therapeutic treatment. Liver biopsy is still the gold standard in order to know the molecular biology of the tumor, its behaviour and invasive characteristics. Conventional diagnosis methods for HCC detection include imaging and serological tests with low sensitivity and specificity. In this review, we focus on the potential utility of certain serum biomarkers and a new approach, "liquid biopsy", in the management of HCC patients.

show abstract

“…Jing et al 18 performed the quantitative reverse transcription polymerase chain reaction (qRT-PCR) assay in 87 pairs of HCC tissues and found that SPRY4-IT1 was remarkably elevated in tumor tissues compared with nontumor tissues. The high level of SPRY4-IT1 was positively associated with tumor differentiation, tumor size, and TNM stage.…”

Section: Hepatocellular Carcinomamentioning

confidence: 99%

SPRY4-IT1: A novel oncogenic long non-coding RNA in human cancers

Chen

et al. 2017

Tumour Biol.

View full text Add to dashboard Cite

Long non-coding RNAs are classified as a kind of RNA, which are longer than 200 nucleotides in length and cannot be translated into proteins. Multiple studies have demonstrated that long non-coding RNAs are involved in various cellular processes, including proliferation, differentiation, cell death, and metastasis. Among numerous long non-coding RNAs, we focus on Sprouty4-Intron 1 (SPRY4-IT1), a well-known long non-coding RNA that is overexpressed in various kinds of tumor tissues and cell lines. Accumulating evidences show that SPRY4-IT1 was dysregulated in various cancers, including melanoma, breast cancer, esophageal squamous cell carcinoma, non-small cell lung cancer, gastric cancer, colon cancer, and hepatocellular carcinoma, and amplification of SPRY4-IT1 was associated with different clinicopathological features of cancer patients. Importantly, SPRY4-IT1 exerts important roles in tumor progression and metastasis. However, detailed molecular mechanisms of SPRY4-IT1 in cancer progression and metastasis were poorly understood. In this review, we have focused on the characteristics of SPRY4-IT1 and illustrated the biological function and mechanism of SPRY4-IT1 in cancer development.

show abstract

Potential diagnostic value of lncRNA SPRY4-IT1 in hepatocellular carcinoma

Cited by 55 publications

References 42 publications

Prognostic role of the long non-coding RNA, SPRY4 Intronic Transcript 1, in patients with cancer: a meta-analysis

Prognostic role of the long non-coding RNA, SPRY4 Intronic Transcript 1, in patients with cancer: a meta-analysis

Performance of different biomarkers for the management of hepatocellular carcinoma

SPRY4-IT1: A novel oncogenic long non-coding RNA in human cancers

Contact Info

Product

Resources

About